Barclays Downgrades Myriad Genetics (MYGN) to Equalweight

August 10, 2016 7:40 AM EDT
Get Alerts MYGN Hot Sheet
Price: $19.72 +0.77%

Rating Summary:
    7 Buy, 16 Hold, 6 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MYGN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Barclays downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Equalweight with a price target of $24.00 (from $50.00).

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $29.46 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades

Related Entities


Add Your Comment